Insulin, isophane
As of the edition of 20 October 2026, Insulin, isophane is a protein: marketed, first approved in 2016 (ES); acts on INSR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2019
- Kind
- Protein
- Brand name
- Humulina Nph
- First approved
- 15 February 2016 (ES)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- FUNDAÇÃO EZEQUIEL DIAS - FUNED; 3 holders in all
- Registered trials
- 2, 1 stopped early
- Disease areas
- Hormones; Nutrition and metabolism; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| INSR | Insulin receptor | P06213 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 4 | 2 | 1 | 0 | 1 |
| All trials | 2 |